AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price
ByAinvest
Friday, Jul 11, 2025 5:21 pm ET1min read
InflaRx, a clinical-stage biopharmaceutical company, received a Nasdaq deficiency notice due to its minimum bid price below $1. The company focuses on developing monoclonal antibodies for inflammatory diseases. Its lead product, IFX-1, is in Phase II trials for Hidradenitis Suppurativa and ANCA-associated vasculitis, while IFX-2 is in preclinical development. InflaRx must regain compliance with Nasdaq's listing requirements within 180 days.
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics, has received a Nasdaq deficiency notice on July 11, 2025. The notice indicates that the company's common shares have closed below the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days, as per Nasdaq Listing Rule 5450(a)(1) [1].In accordance with Nasdaq Listing Rule 5810(c)(3)(A), InflaRx has been granted an initial period of 180 calendar days, or until January 7, 2026, to regain compliance [1]. If the company fails to meet the minimum bid price requirement within this period, it may consider transferring its securities from the Nasdaq Global Select Market to the Nasdaq Capital Market. This transfer could provide an additional 180 days, or until July 6, 2026, to regain compliance, provided that InflaRx meets the applicable market value of publicly held shares and other listing requirements [1].
InflaRx's lead product, vilobelimab, is currently in Phase II trials for Hidradenitis Suppurativa and ANCA-associated vasculitis, while IFX-2 is in preclinical development. The company's focus on developing monoclonal antibodies for inflammatory diseases underscores its potential in the biopharmaceutical sector [1].
The Nasdaq deficiency notice has no immediate effect on InflaRx's listing status or the trading of its shares. The company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule [1].
References:
[1] https://www.morningstar.com/news/globe-newswire/9493299/inflarx-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet